Since it has been verified that albumosomes trap several client proteins, through which the mitochondrial homeostasis is influenced, and Hsp90 inhibitor 17-AAG triggers albumosomal accumulation, we tried to determine whether Hsp90 inhibition could suppress NAFLD progression in a mouse model. This evidence concerns the gene HSP90AB1 and metabolic dysfunction-associated steatotic liver disease.